Stocks
Vertex’s Casgevy Approved for Children as Young as Two
Vertex Pharmaceuticals (VRTX) has received US FDA approval for its gene therapy Casgevy, expanding its indication to children as young as two...
#gene therapy 2 articles
Stocks
FDA Greenlights uniQure’s AMT-130 Data for Accelerated Approval Filing
uniQure's stock surged after the FDA indicated that three-year Phase I/II data for its Huntington's disease gene therapy, AMT-130, could support an...